German molecular diagnostics company Epigenomics said this week that it has granted to Warnex Medical Laboratories a non-exclusive license for Epigenomics' colorectal cancer biomarker Septin9.

Under the terms of the agreement, Warnex, based in Laval, Quebec, has the rights to establish a PCR-based laboratory-developed test for Septin9 and offer colorectal cancer blood testing services in Canada. Warnex said that it plans to launch the testing service in the next few months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.